DelveInsight’s, “Gastrointestinal Stromal Tumors Pipeline Insight 2023” report provides comprehensive insights about 25+ companies and 28+ pipeline drugs in Gastrointestinal Stromal Tumors pipeline landscape. It covers the Gastrointestinal Stromal Tumor pipeline drug profiles, including Gastrointestinal Stromal Tumor clinical trials and nonclinical stage products. It also covers the Gastrointestinal Stromal Tumor pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Gastrointestinal Stromal Tumor Emerging drugs, the Gastrointestinal Stromal Tumor pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Gastrointestinal Stromal Tumor pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
In the Gastrointestinal Stromal Tumor Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Gastrointestinal Stromal Tumor clinical trials studies, Gastrointestinal Stromal Tumor NDA approvals (if any), and product development activities comprising the technology, Gastrointestinal Stromal Tumor collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Gastrointestinal Stromal Tumor Pipeline Report
Request a sample and discover the recent breakthroughs happening in the Gastrointestinal Stromal Tumor Pipeline landscape @ Gastrointestinal Stromal Tumor Pipeline Outlook Report
Gastrointestinal Stromal Tumor Overview
Gastrointestinal Stromal Tumors (GIST) (GISTs) are among a group of cancers known as sarcomas. GISTs belong to the family of sarcomas, which are malignant tumors that arise from various tissues, including fat, muscle, nerves, cartilage, bone, blood vessels, and lymphatic vessels. This distinguishes sarcomas from carcinomas, which arise from the lining of organs/tissues (e.g., lung, colon, breast, prostate, and pancreas), lymphomas, which arise from immune cells in lymph nodes, and leukemias, which arise from immune cells in the bone marrow. GIST can present with a wide spectrum of subjective symptoms, such as nausea, early satiety, bloating, and weight loss. Patients can also experience objective signs of a tumor, such as anemia (low red blood cell count) or a lump in the abdomen. These signs and symptoms depend on the tumor location (e.g., stomach versus rectum), size, and pattern of growth.
Recent Developmental Activities in the Gastrointestinal Stromal Tumors Treatment Landscape
For further information, refer to the detailed Gastrointestinal Stromal Tumor Drugs Launch, Gastrointestinal Stromal Tumor Developmental Activities, and Gastrointestinal Stromal Tumor News, click here for Gastrointestinal Stromal Tumor Ongoing Clinical Trial Analysis
Gastrointestinal Stromal Tumor Emerging Drugs Profile
Famitinib, an orally active, small molecule, is a tyrosine kinase inhibitor against multiple targets, including vascular endothelial growth factor receptor 2/3, platelet-derived growth factor receptor, and stem cell factor receptor (c-kit). Jiangsu Hengrui Medicine Co is developing famitinib against a wide variety of advanced-stage solid cancers. The drug is currently in phase 3 of clinical development for the treatment of Gastrointestinal Stromal Tumors (GIST).
Tasigna (nilotinib hydrochloride monohydrate) is an orally available signal transduction inhibitor of the Bcr-Abl kinase, c-kit and Platelet Derived Growth Factor (PDGF), all of which play a role in cell proliferation, cell migration, and angiogenesis. Tasigna is specifically indicated for the treatment of chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (CML) in adult patients resistant or intolerant to prior therapy that included imatinib. The drug is currently being investigated in Phase II clinical trial to evaluate its potential for the treatment of gastrointestinal stromal tumors.
THE-630 is a pan-variant inhibitor of the receptor tyrosine kinase KIT. It is designed for patients with advanced GIST whose cancer has developed resistance to earlier lines of therapy by accruing mutations that render those therapies ineffective. In GIST, these mutations occur most often in the KIT protein, where a patient can have multiple KIT mutations simultaneously, leading to complex disease heterogeneity. In preclinical studies, THE-630 demonstrated potent in vitro and in vivo activity against all major classes of KIT activating and resistance mutations in GIST. Moreover, THE-630 achieved predicted pan-variant KIT inhibitory blood concentrations at tolerable doses and was associated with significant anti-tumor activity. Theseus Pharmaceuticals is currently conducting Phase I/II study to evaluate lead candidate, THE-630, in patients with advanced gastrointestinal stromal tumors (GIST).
DS-6157 is a potential first-in-class GPR20 targeting ADC and the fifth DXd ADC in the oncology pipeline of Daiichi Sankyo to enter clinical development. ADCs are targeted cancer medicines that deliver cytotoxic chemotherapy (“payload”) to cancer cells via a linker attached to a monoclonal antibody that binds to a specific target expressed on cancer cells. Designed utilizing Daiichi Sankyo’s proprietary DXd ADC technology, DS-6157 is comprised of a humanized anti-GPR20 monoclonal antibody, which is attached to a novel topoisomerase I inhibitor payload by a tetrapeptide-based linker. The drug is currently in Phase I stage of clinical trial evaluation to treat Gastrointestinal Stromal Tumors.
Gastrointestinal Stromal Tumor Pipeline Therapeutics Assessment
There are approx. 25+ key companies which are developing the therapies for Gastrointestinal Stromal Tumors. The companies which have their Gastrointestinal Stromal Tumors drug candidates in the most advanced stage, i.e. phase III include, Jiangsu Hengrui Medicine.
Find out more about the Gastrointestinal Stromal Tumor Pipeline Segmentation, Therapeutics Assessment, and Gastrointestinal Stromal Tumor Emerging Drugs @ Gastrointestinal Stromal Tumor Treatment Landscape
Scope of the Gastrointestinal Stromal Tumor Pipeline
Dive deep into rich insights for drugs for Gastrointestinal Stromal Tumor Pipeline Companies and Therapies, click here @ Gastrointestinal Stromal Tumor Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Gastrointestinal Stromal Tumor Mergers and acquisitions, Gastrointestinal Stromal Tumor Licensing Activities @ Gastrointestinal Stromal Tumor Recent Trends, and Future Perspectives
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/